ML327 is a small molecule inhibitor primarily researched for its ability to disrupt the protein-protein interaction between N-Myc and Aurora A, which is crucial for the stability and oncogenic activity of N-Myc in cancers such as neuroblastoma. By promoting N-Myc degradation, ML327 inhibits cancer cell growth and metastasis. It has also shown promise in blocking the EMT (Epithelial-Mesenchymal Transition) process, reducing the spread of cancer cells. Additionally, ML327 enhances the efficacy of chemotherapy by sensitizing cancer cells to treatment. Beyond oncology, it is being explored for treating fibrotic diseases by targeting pathways involved in tissue scarring. Its applications remain in experimental and preclinical stages with significant therapeutic potential.